Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
3/1/23	G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
2/28/23	G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
2/22/23	G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
2/13/23	G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
2/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/11/23	G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
1/9/23	G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
1/4/23	G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
1/3/23	G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference